J. Molner’s Post

Pharmacy is a mess, and the White House knows it. Check out their roundtable summarizing the big issues in pharmacy. --- Monday, the White House hosted a roundtable on lowering #HealthcareCosts and bringing #transparency to prescription drug middlemen. It's an hour long on Youtube (link in the comments) OR 30 minutes if you go with 2x speed 😉 --- The information shared likely isn't new or surprising to anyone here, but it's a great summary of the problems in #pharmacy right now. Some of the topics discussed: - Anticompetitive practices by PBMs - Pharmacy reimbursement - Restriction of access to prescriptions - Transparent pricing - #DrugShortages - Generic drug manufacturing --- The panel was full of very knowledgeable people in the drug supply chain. It's worth the time to review the video and/or send to those who don't understand why pharmacy is having so many problems. HHS Secretary Xavier Becerra Lina Khan Andy Beshear for Governor Dared Price Chichi Ilonzo Momah, PharmD Mark Cuban Alex Oshmyansky, MD, PhD Sandra Clark, MPH

When it comes to prescription drugs and access to care, employers are facing rising costs and complex challenges. Our latest insights are all about managing #pharmacy benefits, covering key factors and effective strategies to help employers and health plan sponsors navigate the landscape of prescription drug costs. Read more 🔗 https://lnkd.in/ev_rvadc #TheBaldwinGroup #ProtectingThePossible #EmployeeBenefits

  Hi, We thought you might be interested in an article we recently came across, titled "Prescription Drug Pricing Trends". It discusses current trends in the cost of prescription drugs and offers practical guidance for employers to help manage and potentially reduce health care expenditures. Thanks, William Cross  

When it comes to prescription drugs and access to care, employers are facing rising costs and complex challenges. Our latest insights are all about managing hashtag #pharmacy benefits, covering key factors and effective strategies to help employers and health plan sponsors navigate the landscape of prescription drug costs. Read more 🔗 https://lnkd.in/ev_rvadc #TheBaldwinGroup #ProtectingThePossible #EmployeeBenefits

What role has the evolution of pharmacy benefit managers (PBMs) in recent decades played in the U.S. prescription drug market? Find this out and more as experts discuss with JAMA Health Forum. https://lnkd.in/gKdnmY5Y

Medicare drug pricing negotiations kicked off earlier this month, and it's one for pharmacies & consumers to watch. For the first time, the federal government is proposing tying a medication's price to effectiveness compared to similar treatments. The move brings the U.S. in line with other similar countries that already make these kinds of value assessments when pricing drugs. "The fact that America is in a sense joining the rest of the developed world in realizing they can't assume the market will fix everything with value, price, and access — that's a big deal," said Steve Pearson, founder of the Institute for Clinical and Economic Review (ICER), an independent organization that assesses the value of medical treatments. #Pharmacy #DrugPricing #Healthcare #FutureofHealthcare

Our 2023 drug trends report analyzes data from in- and out-of-network pharmacy channels to offer a complete view of #workcomp prescription activity. It provides insights that traditional industry reports don’t include. To see the bigger picture, download the report now. https://lnkd.in/eQEbrJZw

What U.S. drug trends will impact your pharmacy benefit plans in 2024? Michael Kleinrock shared the latest drug trends benefit advisors need to know for 2024 in our latest webinar. Here are the highlights: https://rxbene.fit/3GRaFYU

In the era of the Inflation Reduction Act, trust Qlarant to lead the way in Drug Pricing and Pharmacy data solutions.

The more we understand about pharmacy pricing, then better we will be in finding equitable solutions. First ever survey results with reactions! Followed by discussion, case reports and expert opinions. Goal is to help you start asking questions you may not have been aware of to ask.